Accuray (NASDAQ:ARAY) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell?

Accuray Incorporated (NASDAQ:ARAY - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.86 and traded as high as $1.87. Accuray shares last traded at $1.87, with a volume of 633,664 shares changing hands.

Accuray Price Performance

The company's 50 day moving average price is $1.95 and its 200 day moving average price is $1.86. The company has a debt-to-equity ratio of 3.65, a quick ratio of 0.95 and a current ratio of 1.66. The company has a market cap of $184.59 million, a price-to-earnings ratio of -8.43 and a beta of 1.39.

Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported $0.03 EPS for the quarter, meeting analysts' consensus estimates of $0.03. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.65%. The firm had revenue of $134.29 million for the quarter, compared to analyst estimates of $122.80 million. During the same period in the previous year, the business earned ($0.03) earnings per share. On average, equities research analysts predict that Accuray Incorporated will post -0.01 earnings per share for the current fiscal year.

Institutional Trading of Accuray

A number of hedge funds and other institutional investors have recently made changes to their positions in ARAY. US Bancorp DE lifted its holdings in Accuray by 1,087.7% during the 3rd quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider's stock worth $32,000 after buying an additional 16,316 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Accuray by 127.1% during the third quarter. Assenagon Asset Management S.A. now owns 164,999 shares of the medical equipment provider's stock valued at $297,000 after acquiring an additional 92,357 shares during the period. SG Americas Securities LLC acquired a new position in shares of Accuray during the third quarter valued at $59,000. The Manufacturers Life Insurance Company increased its position in Accuray by 13.3% in the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider's stock worth $82,000 after purchasing an additional 5,273 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Accuray in the second quarter worth about $30,000. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.